LGVNR and LGVN Related Headlines
Go Back- Longeveron publishes Phase 2b stem cell trial results in Cell Stem Cell
- Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell
- Longeveron appoints Stephen Willard as CEO
- Longeveron® Appoints Stephen H. Willard as Chief Executive Officer
- Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program
- Longeveron receives Japan patent for stem cell potency testing methods
- Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
- Longeveron gets FDA Type C meeting for rare heart condition trial
- Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
- Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026
- Longeveron receives patent for stem cell therapy treating female sexual dysfunction
- Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy
- Longeveron executives to speak at cardiovascular clinical trials forum
- Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum
- Longeveron receives Canadian patent for stem cell treatments
- Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging
- Longeveron presents MRI data on stem cell therapy for Alzheimer's
- Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD
- Longeveron selected for Alzheimer's poster at CTAD 2025 conference
- Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)
- Longeveron receives US patent for stem cell therapy treating frailty
- Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy
- Longeveron® Announces Third Quarter 2025 Financial Results and Provides Business Update
- Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
- Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR’s BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS),
- Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
- Longeveron adds orthopedic surgeon George Paletta to board
- George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors
- Longeveron® to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa
- Longeveron appoints Than Powell as interim CEO, Joshua Hare as chairman
- Longeveron® Announces Key Leadership Updates
- Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference
- Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update
- Longeveron closes $5 million public offering with warrant potential
- Longeveron Announces Closing Of Up To $17.5 Million Public Offering
- Longeveron prices $5 million public offering with warrants
- Longeveron Announces Up To $17.5 Million Public Offering
- Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025
- Longeveron licenses stem cell patent from University of Miami
- Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease
- Longeveron gets FDA approval for pediatric heart disease trial
- Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)
- Longeveron (LGVN) Appoints Than Powell as Chief Business Officer
- Longeveron® Appoints Than Powell as Chief Business Officer
- Longeveron (LGVN) Completes Enrollment of Pivotal Phase 2b Trial of Laromestrocel
- Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)
LGVNR and LGVN Related Press Releases
Go Back- Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell
- Longeveron® Appoints Stephen H. Willard as Chief Executive Officer
- Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program
- Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
- Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
- Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026
- Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy
- Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum
- Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging
- Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD
- Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)
- Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy
- Longeveron® Announces Third Quarter 2025 Financial Results and Provides Business Update
- Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
- Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR’s BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS),
- Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
- George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors
- Longeveron® to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa
- Longeveron® Announces Key Leadership Updates
- Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference
- Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update
- Longeveron Announces Closing Of Up To $17.5 Million Public Offering
- Longeveron Announces Up To $17.5 Million Public Offering
- Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025
- Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease
- Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)
- Longeveron® Appoints Than Powell as Chief Business Officer
- Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)
